Loading
Endoplasmic Reticulum Stress and Disease · Journal article
Pharmaceuticals · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining ADAR1 as a pan-cancer therapeutic target through its role in suppressing dsRNA sensing pathways (PKR, MDA5, OAS) and identifying a therapeutic vulnerability in tumors with elevated interferon-stimulated gene expression. The review organizes ADAR1 modulators into mechanistic classes and discusses combination strategies, but presents no new clinical evidence, trial results, or comparative efficacy data.
Journal article. Tumors characterized by elevated interferon-stimulated gene expression and dsRNA stress (not a studied cohort; a theoretical population)..
ADAR1 suppresses activation of dsRNA sensing pathways (PKR, MDA5, OAS) through A-to-I editing and editing-independent mechanisms. A subset of tumors with elevated interferon-stimulated gene expression and dsRNA stress show dependency on ADAR1 for survival, creating a therapeutic vulnerability. ADAR1 modulators are classified into six mechanistic categories: nucleoside analogs, catalytic inhibitors, Zα domain modulators, RNA substrate engagement inhibitors, indirect pathway regulators, and PROTACs.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a conceptual framework for understanding ADAR1 as a therapeutic target and organizing drug classes, but clinicians and researchers should recognize it reports no efficacy or safety data from trials and does not provide evidence for clinical action.
This is a narrative review of biological mechanisms and therapeutic strategies with no primary experimental results, efficacy data, or clinical evidence; it organizes existing knowledge and raises questions for future investigation.
This review provides a conceptual framework for understanding ADAR1 as a therapeutic target and organizing drug classes, but clinicians and researchers should recognize it reports no efficacy or safety data from trials and does not provide evidence for clinical action.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Adenosine deaminase acting on RNA 1 (ADAR1) is a critical regulator of innate immune signaling and a pan-cancer therapeutic target. Through catalyzing adenosine-to-inosine (A-to-I) editing and editing-independent mechanisms, ADAR1 suppresses activation of dsRNA sensing pathways, including protein kinase R (PKR), melanoma differentiation-associated protein 5 (MDA5), and oligodenylate-synthetase (OAS) signaling, that are critical for maintaining cellular tolerance to endogenous RNAs. In a subset of tumors characterized by elevated interferon-stimulated gene (ISG) expression and dsRNA stress, this function creates a dependency on ADAR1 for survival, establishing a therapeutic vulnerability that can be exploited to induce viral mimicry in cancer cells and enhance anti-tumor immune responses. Here, we review the emerging landscape of ADAR1 modulators, organizing reported compounds into mechanistic classes including nucleoside analogs, catalytic inhibitors, Zα domain modulators, RNA substrate engagement inhibitors, indirect pathway regulators, and PROTACs. We evaluate molecules within these classes with a focus on their mechanisms of action and experimental validation. We further discuss the challenges associated with distinguishing direct inhibition of ADAR1 activity from broader effects on RNA metabolism and innate immune activation. Finally, we highlight the therapeutic potential of ADAR1 targeting defined cancer subsets and examine combination strategies that leverage ADAR1 inhibition for improved sensitivity to current cancer therapeutics. Overall, this review outlines key considerations for the development of selective therapies targeting ADAR1.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.